-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-500479-29-00
10
2023-03-28
International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
-
2023-509672-42-00
5
2023-02-02
GRIN-related neurodevelopmental disorder
-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2022-500391-62-00
9
2023-01-19
Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2022-501374-19-00
4
2022-09-16
Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chr
-
2023-509936-25-00
4
2022-06-09
Transplant Rejection
-
2023-509715-91-00
5
2022-05-06
Fabry’s disease
-
2023-506145-38-00
3
2021-05-11
Treatment of participants with MF, MDS, ET, or MDS/MPN
-
2023-508883-31-00
5
2021-02-23
Solid tumors and hamatological malignancies
-
2024-511267-28-00
5
2021-02-17
B-cell malignancies
-
2022-501687-18-00
4
2020-10-28
Advanced malignancies and IAI diseases
-
2023-510509-17-00
7
2020-06-17
Relapsed and/or refractory Acute Myeloid Leukemia
-
2023-510504-45-00
4
2026-05-14
unresectable hepatocellular carcinoma (HCC)
-
2024-520441-23-00
5
2026-05-13
Overweight or obesity, and type 2 diabetes
-
2024-516993-31-00
5
2026-05-11
Renal Cell Carcinoma
-
2025-523123-22-00
5
2026-05-07
Chronic Kidney Disease
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-523804-62-00
5
2026-04-28
Obesity
-
2023-505185-28-00
3
2026-04-23
Non-Hodgkin Lymphoma
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2024-517490-24-00
4
2026-03-31
Small Cell Lung Cancer